Only two anticancer nanoparticles are used as front-line therapies: nanoparticle albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) for advanced non-small cell lung cancer and metastatic pancreatic adenocarcinoma, and liposomal daunorubicin cytarabine (CPX-351; Vyxeos®) for treatment-related acute myeloid leukemia and acute myeloid leukemia with myelodysplastic changes. This evidence concerns the gene ALB and non-small cell lung carcinoma.